BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

Clinical trial NCT04752826 · RECRUITING

Trial details

NCT number: NCT04752826
Sponsor: BioInvent International AB
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advanced Malignancies Ovarian Cancer T-cell Lymphoma Melanoma

Start date: 2021-01-25
Primary completion: 2026-12-31
Enrollment: 176

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.